|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRIP1 |
Gene summary for GRIP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRIP1 | Gene ID | 23426 |
| Gene name | glutamate receptor interacting protein 1 | |
| Gene Alias | FRASRS3 | |
| Cytomap | 12q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9Y3R0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23426 | GRIP1 | CCI_1 | Human | Cervix | CC | 4.06e-19 | 1.41e+00 | 0.528 |
| 23426 | GRIP1 | CCI_3 | Human | Cervix | CC | 1.85e-34 | 1.48e+00 | 0.516 |
| 23426 | GRIP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.36e-21 | -7.03e-01 | 0.0155 |
| 23426 | GRIP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.83e-15 | -7.43e-01 | -0.1808 |
| 23426 | GRIP1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.77e-03 | -6.16e-01 | 0.0216 |
| 23426 | GRIP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.85e-06 | -5.77e-01 | -0.0811 |
| 23426 | GRIP1 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.46e-09 | -6.12e-01 | -0.1088 |
| 23426 | GRIP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.64e-16 | -6.13e-01 | -0.1954 |
| 23426 | GRIP1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.50e-09 | -6.50e-01 | -0.1207 |
| 23426 | GRIP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 9.59e-09 | -7.33e-01 | -0.1526 |
| 23426 | GRIP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.52e-25 | -6.05e-01 | -0.1464 |
| 23426 | GRIP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.87e-14 | -5.80e-01 | -0.1001 |
| 23426 | GRIP1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.68e-17 | -6.46e-01 | -0.059 |
| 23426 | GRIP1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.79e-02 | -5.17e-01 | -0.1706 |
| 23426 | GRIP1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.70e-05 | -7.03e-01 | -0.2061 |
| 23426 | GRIP1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.59e-03 | -6.74e-01 | -0.1462 |
| 23426 | GRIP1 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.99e-05 | -5.08e-01 | -0.0842 |
| 23426 | GRIP1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 5.39e-08 | -8.14e-01 | -0.0179 |
| 23426 | GRIP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.30e-06 | -4.62e-01 | 0.096 |
| 23426 | GRIP1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.47e-03 | -6.29e-01 | 0.0528 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
| GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
| GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
| GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:00988767 | Cervix | CC | vesicle-mediated transport to the plasma membrane | 34/2311 | 136/18723 | 3.75e-05 | 5.91e-04 | 34 |
| GO:00901509 | Cervix | CC | establishment of protein localization to membrane | 54/2311 | 260/18723 | 7.67e-05 | 1.05e-03 | 54 |
| GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
| GO:00619516 | Cervix | CC | establishment of protein localization to plasma membrane | 16/2311 | 60/18723 | 2.00e-03 | 1.46e-02 | 16 |
| GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
| GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
| GO:0090150 | Colorectum | AD | establishment of protein localization to membrane | 100/3918 | 260/18723 | 6.01e-11 | 6.33e-09 | 100 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0022604 | Colorectum | AD | regulation of cell morphogenesis | 109/3918 | 309/18723 | 3.08e-09 | 2.07e-07 | 109 |
| GO:0098876 | Colorectum | AD | vesicle-mediated transport to the plasma membrane | 57/3918 | 136/18723 | 2.30e-08 | 1.27e-06 | 57 |
| GO:0061951 | Colorectum | AD | establishment of protein localization to plasma membrane | 31/3918 | 60/18723 | 1.37e-07 | 6.42e-06 | 31 |
| GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
| GO:0032456 | Colorectum | AD | endocytic recycling | 28/3918 | 73/18723 | 4.87e-04 | 5.30e-03 | 28 |
| GO:0016358 | Colorectum | AD | dendrite development | 69/3918 | 243/18723 | 3.32e-03 | 2.42e-02 | 69 |
| GO:1902414 | Colorectum | AD | protein localization to cell junction | 31/3918 | 94/18723 | 4.30e-03 | 2.95e-02 | 31 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRIP1 | SNV | Missense_Mutation | novel | c.2028G>C | p.Leu676Phe | p.L676F | Q9Y3R0 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| GRIP1 | SNV | Missense_Mutation | c.1819G>C | p.Asp607His | p.D607H | Q9Y3R0 | protein_coding | tolerated(0.05) | benign(0.443) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GRIP1 | SNV | Missense_Mutation | rs141923622 | c.644C>T | p.Thr215Met | p.T215M | Q9Y3R0 | protein_coding | deleterious(0) | probably_damaging(0.918) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRIP1 | SNV | Missense_Mutation | c.3211N>A | p.Glu1071Lys | p.E1071K | Q9Y3R0 | protein_coding | deleterious_low_confidence(0.03) | benign(0.037) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| GRIP1 | SNV | Missense_Mutation | rs753434168 | c.3209G>A | p.Arg1070Gln | p.R1070Q | Q9Y3R0 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.852) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| GRIP1 | insertion | Frame_Shift_Ins | novel | c.172_173insTGTGGGT | p.Lys58MetfsTer18 | p.K58Mfs*18 | Q9Y3R0 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| GRIP1 | insertion | Nonsense_Mutation | novel | c.170_171insTTTGCAGAAGTGACCAGCTG | p.Met57IlefsTer5 | p.M57Ifs*5 | Q9Y3R0 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| GRIP1 | insertion | Frame_Shift_Ins | novel | c.2725_2726insAAGATGTGTTAGATGTCTTGGGCCAGGATAA | p.Arg909GlnfsTer29 | p.R909Qfs*29 | Q9Y3R0 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GRIP1 | insertion | Nonsense_Mutation | novel | c.2717_2718insATAGACAAATAGCAAGTATAAAA | p.Ser906ArgfsTer2 | p.S906Rfs*2 | Q9Y3R0 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GRIP1 | SNV | Missense_Mutation | novel | c.356N>A | p.Ser119Asn | p.S119N | Q9Y3R0 | protein_coding | tolerated(0.24) | benign(0.02) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |